399 related articles for article (PubMed ID: 25774849)
21. Early environmental therapy rescues brain development in a mouse model of Down syndrome.
Begenisic T; Sansevero G; Baroncelli L; Cioni G; Sale A
Neurobiol Dis; 2015 Oct; 82():409-419. PubMed ID: 26244989
[TBL] [Abstract][Full Text] [Related]
22. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome.
Harashima C; Jacobowitz DM; Witta J; Borke RC; Best TK; Siarey RJ; Galdzicki Z
J Comp Neurol; 2006 Feb; 494(5):815-33. PubMed ID: 16374808
[TBL] [Abstract][Full Text] [Related]
23. Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
Siarey RJ; Kline-Burgess A; Cho M; Balbo A; Best TK; Harashima C; Klann E; Galdzicki Z
J Neurochem; 2006 Aug; 98(4):1266-77. PubMed ID: 16895585
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of tonic GABA currents following epileptogenic stimulation of rat hippocampal cultures.
Qi JS; Yao J; Fang C; Luscher B; Chen G
J Physiol; 2006 Dec; 577(Pt 2):579-90. PubMed ID: 16990405
[TBL] [Abstract][Full Text] [Related]
25. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
Dzhala VI; Brumback AC; Staley KJ
Ann Neurol; 2008 Feb; 63(2):222-35. PubMed ID: 17918265
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model.
Das I; Park JM; Shin JH; Jeon SK; Lorenzi H; Linden DJ; Worley PF; Reeves RH
Sci Transl Med; 2013 Sep; 5(201):201ra120. PubMed ID: 24005160
[TBL] [Abstract][Full Text] [Related]
27. Fast Regulation of GABA
Fricke S; Metzdorf K; Ohm M; Haak S; Heine M; Korte M; Zagrebelsky M
Cell Rep; 2019 Oct; 29(3):671-684.e6. PubMed ID: 31618635
[TBL] [Abstract][Full Text] [Related]
28. Altered synaptic dynamics and hippocampal excitability but normal long-term plasticity in mice lacking hyperpolarizing GABA A receptor-mediated inhibition in CA1 pyramidal neurons.
Riekki R; Pavlov I; Tornberg J; Lauri SE; Airaksinen MS; Taira T
J Neurophysiol; 2008 Jun; 99(6):3075-89. PubMed ID: 18436638
[TBL] [Abstract][Full Text] [Related]
29. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current.
Best TK; Siarey RJ; Galdzicki Z
J Neurophysiol; 2007 Jan; 97(1):892-900. PubMed ID: 17093127
[TBL] [Abstract][Full Text] [Related]
30. Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model.
Segovia-Miranda F; Serrano F; Dyrda A; Ampuero E; Retamal C; Bravo-Zehnder M; Parodi J; Zamorano P; Valenzuela D; Massardo L; van Zundert B; Inestrosa NC; González A
Arthritis Rheumatol; 2015 Jun; 67(6):1598-610. PubMed ID: 25709106
[TBL] [Abstract][Full Text] [Related]
31. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome.
Di Filippo M; Tozzi A; Ghiglieri V; Picconi B; Costa C; Cipriani S; Tantucci M; Belcastro V; Calabresi P
Biol Psychiatry; 2010 Apr; 67(7):666-71. PubMed ID: 19818432
[TBL] [Abstract][Full Text] [Related]
32. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.
Costa AC; Grybko MJ
Neurosci Lett; 2005 Jul; 382(3):317-22. PubMed ID: 15925111
[TBL] [Abstract][Full Text] [Related]
33. NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity.
O'Mahony A; Raber J; Montano M; Foehr E; Han V; Lu SM; Kwon H; LeFevour A; Chakraborty-Sett S; Greene WC
Mol Cell Biol; 2006 Oct; 26(19):7283-98. PubMed ID: 16980629
[TBL] [Abstract][Full Text] [Related]
34. Developmental excitatory-to-inhibitory GABA-polarity switch is disrupted in 22q11.2 deletion syndrome: a potential target for clinical therapeutics.
Amin H; Marinaro F; De Pietri Tonelli D; Berdondini L
Sci Rep; 2017 Nov; 7(1):15752. PubMed ID: 29146941
[TBL] [Abstract][Full Text] [Related]
35. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
[TBL] [Abstract][Full Text] [Related]
36. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.
Cramer N; Galdzicki Z
Neural Plast; 2012; 2012():101542. PubMed ID: 22848844
[TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.
Fernandez F; Morishita W; Zuniga E; Nguyen J; Blank M; Malenka RC; Garner CC
Nat Neurosci; 2007 Apr; 10(4):411-3. PubMed ID: 17322876
[TBL] [Abstract][Full Text] [Related]
38. Acute and chronic efficacy of bumetanide in an in vitro model of posttraumatic epileptogenesis.
Dzhala V; Staley KJ
CNS Neurosci Ther; 2015 Feb; 21(2):173-80. PubMed ID: 25495911
[TBL] [Abstract][Full Text] [Related]
39. G-protein-associated signal transduction processes are restored after postweaning environmental enrichment in Ts65Dn, a Down syndrome mouse model.
Baamonde C; Martínez-Cué C; Flórez J; Dierssen M
Dev Neurosci; 2011; 33(5):442-50. PubMed ID: 21865666
[TBL] [Abstract][Full Text] [Related]
40. Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex.
Conti L; Palma E; Roseti C; Lauro C; Cipriani R; de Groot M; Aronica E; Limatola C
Epilepsia; 2011 Sep; 52(9):1635-44. PubMed ID: 21635237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
